The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans
Abstract
Scope: Trisomy for human chromosome 21 results in D own syndrome (DS), which is among the most complex genetic perturbations leading to intellectual disability. Accumulating data suggest that overexpression of the dual‐specificity tyrosine‐(Y)‐phosphorylation regulated kinase 1A (DYRK 1 A), is a critical pathogenic mechanisms in the intellectual deficit. Methods and results: Here we show that the green tea flavonol epigallocatechin‐gallate (EGCG), a DYRK 1 A inhibitor, rescues the cognitive deficits of both segmental trisomy 16 (T s65 D n) and transgenic mice overexpressing Dyrk1A in a trisomic or disomic genetic background, respectively. It also significantly reverses cognitive deficits in a pilot study in DS individuals with effects on memory recognition, working memory and quality of life. We used the mouse models to ensure that EGCG was able to reduce DYRK 1 A kinase activity in the hippocampus and found that it also induced significant changes in plasma homocysteine levels, which were correlated with Dyrk1A expression levels. Thus, we could use plasma homocysteine levels as an efficacy biomarker in our human study. Conclusion: We conclude that EGCG is a promising therapeutic tool for cognitive enhancement in DS, and its efficacy may depend of Dyrk1A inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“EGCG is a potent and selective inhibitor of DYRK1A activity [22].”
BackgroundA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913
Meunier, M., Bachevalier, J., Mishkin, M., & Murray, E. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-12-05418.1993 · Cited by 901
Winters, B. D., Forwood, S. E., Cowell, R. A., Saksida, L. M., & Bussey, T. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1346-04.2004 · Cited by 586
Anti‐infective properties of epigallocatechin‐3‐gallate (EGCG), a component of green tea
Steinmann, J., Buer, J., Pietschmann, T., & Steinmann, E. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12009 · Cited by 559
Cognitive deficits and associated neurological complications in individuals with Down's syndrome
Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484
Self-citationNutraceutical Antioxidants as Novel Neuroprotective Agents
Kelsey, N. A., Wilkins, H. M., & Linseman, D. A. (2010) · Molecules · doi:10.3390/molecules15117792 · Cited by 480
Bachevalier, J., & Mishkin, M. (1986) · Behavioural Brain Research · doi:10.1016/0166-4328(86)90225-1 · Cited by 445
Altafaj, X. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1915 · Cited by 396
Effects of Green Tea and EGCG on Cardiovascular and Metabolic Health
Wolfram, S. (2007) · Journal of the American College of Nutrition · doi:10.1080/07315724.2007.10719626 · Cited by 370
Cited by
The safety of green tea and green tea extract consumption in adults – Results of a systematic review
Hu, J., Webster, D., Cao, J., & Shao, A. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.03.019 · Cited by 405
Scientific opinion on the safety of green tea catechins
(ANS), E. P. O. F. A. A. N. S. A. T. F., Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M. J., Galtier, P., Gott, D., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5239 · Cited by 317
Down syndrome and the complexity of genome dosage imbalance
Antonarakis, S. E. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.154 · Cited by 299
de la Torre, R., de Sola, S., Hernandez, G., Farré, M., Pujol, J., Rodriguez, J., Espadaler, J. M., Langohr, K., Cuenca-Royo, A., Principe, A., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30034-5 · Cited by 289
Self-citationBallard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00063-6 · Cited by 264
Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181
Self-citationJi, J., Lee, H., Argiropoulos, B., Dorrani, N., Mann, J., Martinez-Agosto, J. A., Gomez-Ospina, N., Gallant, N., Bernstein, J. A., Hudgins, L., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.71 · Cited by 145
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome
Contestabile, A., Magara, S., & Cancedda, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00054 · Cited by 141
Polyphenols and neuroprotection: therapeutic implications for cognitive decline
Caruso, G., Torrisi, S. A., Mogavero, M. P., Currenti, W., Castellano, S., Godos, J., Ferri, R., Galvano, F., Leggio, G. M., Grosso, G., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108013 · Cited by 140
Neurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120
García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104
García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100
Yan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5288698 · Cited by 97
Yin, X., Jin, N., Shi, J., Zhang, Y., Wu, Y., Gong, C.-X., Iqbal, K., & Liu, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-00682-y · Cited by 93
Najas, S., Arranz, J., Lochhead, P. A., Ashford, A. L., Oxley, D., Delabar, J. M., Cook, S. J., Barallobre, M. J., & Arbonés, M. L. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.01.010 · Cited by 92
Self-citationAtas-Ozcan, H., Brault, V., Duchon, A., & Herault, Y. (2021) · Genes · doi:10.3390/genes12111833 · Cited by 78
Self-citationZhang, S., Zhu, Q., Chen, J.-Y., OuYang, D., & Lu, J.-H. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153316 · Cited by 74
Neumann, F., Gourdain, S., Albac, C., Dekker, A. D., Bui, L. C., Dairou, J., Schmitz-Afonso, I., Hue, N., Rodrigues-Lima, F., Delabar, J. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20984-z · Cited by 71
Self-citationHart, S. J., Visootsak, J., Tamburri, P., Phuong, P., Baumer, N., Hernandez, M., Skotko, B. G., Ochoa‐Lubinoff, C., Liogier D'Ardhuy, X., Kishnani, P. S., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38465 · Cited by 54
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
Goodlett, C. R., Stringer, M., LaCombe, J., Patel, R., Wallace, J. M., & Roper, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67133-z · Cited by 43
Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials
Rueda Revilla, N., & Martínez-Cué, C. (2020) · Antioxidants · doi:10.3390/antiox9080692 · Cited by 35
DYRK1A BAC Transgenic Mouse: A New Model of Thyroid Dysgenesis in Down Syndrome
Kariyawasam, D., Rachdi, L., Carré, A., Martin, M., Houlier, M., Janel, N., Delabar, J.-M., Scharfmann, R., & Polak, M. (2015) · Endocrinology · doi:10.1210/en.2014-1329 · Cited by 30
Self-citationScala, I., Valenti, D., Scotto D’Aniello, V., Marino, M., Riccio, M. P., Bravaccio, C., Vacca, R. A., & Strisciuglio, P. (2021) · Antioxidants · doi:10.3390/antiox10030469 · Cited by 25
“EGCG is also a specific and safe inhibitor of DYRK1A [30] and it was found to improve brain defects induced by DYRK1A overexpression [31,32].”
BackgroundResultInfluentialGenetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21
Mumford, P., Tosh, J., Anderle, S., Gkanatsiou Wikberg, E., Lau, G., Noy, S., Cleverley, K., Saito, T., Saido, T. C., Yu, E., et al. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.0521-22.2022 · Cited by 22
State-of-the-art therapy for down syndrome
Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22
Self-citationRethinking intellectual disability from neuro- to astro-pathology.
Fernández-Blanco, Á., & Dierssen, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239039 · Cited by 19
Self-citationSearching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
Hawley, L. E., Prochaska, F., Stringer, M., Goodlett, C. R., & Roper, R. J. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173404 · Cited by 11
Bhamidimarri, P. M., Alhosani, K., Cai, H., Al-Ali, H., Abukhaled, Y. M., Tawamie, H., Abdelaziz, S., Fawaz, M., Kashir, J., Sajjad, Y., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107227 · Cited by 10
Metadata
- Authors
- De la Torre, R., De Sola, S., Pons, M., Duchon, A., de Lagran, M. M., Farré, M., Fitó, M., Benejam, B., Langohr, K., Rodriguez, J., Pujadas, M., Bizot, J. C., Cuenca, A., Janel, N., Catuara, S., Covas, M. I., Blehaut, H., Herault, Y., Delabar, J. M., & Dierssen, M.
- Venue
- Molecular Nutrition & Food Research
- Publisher
- Wiley
- Published
- 2013-09-14
- Volume
- 58
- Issue
- 2
- Pages
- 278-288
- ISSN
- 1613-4125 (ISSN-L)
- 1613-4133
- OpenAlex
- W2051685982
- Cited by
- 286
- References
- 41
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.